Clinical trials: Test
Cystic Fibrosis
A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1
The primary objective of this trial is to assess the efficacy, safety and pharmacokinetics of twice daily inhaled doses of BI 1265162 delivered by Respimat® inhaler versus placebo in adolescents and adult patients with cystic…
- Trial name
- NCT04059094
- Testing
- BI 1265162
- Where
- 26 sites in United States, Belgium and 6 more
- Volunteers
- 52 people
- Sponsor
- Boehringer Ingelheim
Metastatic Colorectal Cancer (CRC)
A Study to Test Different Doses of BI 1701963 in Combination With Irinotecan in People With Advanced Bowel Cancer With Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutation
This study is open to adults with advanced bowel cancer (colorectal cancer) with a KRAS mutation. This is a study in people for whom previous treatment was not successful and surgery is not a treatment option.
- Trial name
- NCT04627142
- Testing
- BI 1701963, Camptosar®
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Boehringer Ingelheim
Tobacco Use, Smoking
CSD200902: Assessment of Indoor Air Quality for a Heated Tobacco Product With Four Non-Combusted Cigarette Variants in an Environmental Testing Chamber
This is a single-center, open-label, parallel-cohort study to measure and compare the levels of selected secondhand smoke (SHS) constituents of a heated tobacco product (HTP) against combustible cigarettes (CC) after ad libitum…
- Conditions
- Tobacco Use, Smoking, Tobacco Smoking
- Trial name
- NCT05363254
- Testing
- Marlboro Gold Box, Newport Box, Non-combusted cigarette variant 42001401
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Healthy
A Study to Test How Different Doses of BI 765423 Are Taken up in the Body of Healthy Men
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 765423 in healthy male subjects following intravenous administration of single rising doses.
- Trial name
- NCT05658107
- Testing
- BI 765423
- Where
- Belgium
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Colorectal Cancer
Peripheral Blood Monocytes as Predictive Marker for Colorectal Cancer Diagnosis: A Comparative Study of a Stool Based Versus Blood Based Screening Test
In this prospective study, the main goal is to evaluate the strength of Monomark -a monocyte-based transcriptomic test combined to a mathematical model- in patients with a positive FIT test.
- Trial name
- MonoFIT+ (NCT03462992)
- Testing
- MonoMark
- Where
- Belgium
- Volunteers
- 250 people
- Sponsor
- DNAlytics
Kidney Transplant Rejection
Molecular Biomarkers in Renal Transplantation Via TruGraf® Test
The TruGraf® test is a non-invasive blood test that measures molecular gene expression profiles associated with clinical conditions previously only diagnosed by biopsy in kidney transplant recipients.
- Trial name
- NCT04398498
- Testing
- Diagnostic Test: TruGraf® Testing
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Transplant Genomics, Inc.
Acute Pain
Assessment of PF614 Effects on Experimental Pain in the Cold Pressure Test (PF614-201)
The primary objective of the study is to evaluate the onset of analgesia following administration of a single oral dose of PF614 (50 mg or 100 mg) or placebo in healthy male subjects in an experimental pain model (cold pressor…
- Trial name
- CPT (NCT06629402)
- Testing
- PF614
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Ensysce Biosciences
Carcinoma, Non-Small Cell Lung
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.
- Trial name
- ARTEMIDELung04 (NCT06868277)
- Testing
- Rilvegostomig, Pembrolizumab
- Where
- 304 sites in United States, Argentina and 25 more
- Volunteers
- 830 people
- Sponsor
- AstraZeneca
Healthy
Cilostazol 100 mg Tablet Formulations Under Fasting Conditions
The objective of this randomized, single-dose, two-way evaluation is to compare the bioequivalence of a test cilostazol formulation to an equivalent oral dose of the commercially available cilostazol in a test population of 36…
- Trial name
- NCT00838630
- Testing
- Cilostazol 100 mg tablets, Pletal® 100 mg tablets
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Healthy
A Study in Healthy Men to Test if Taking Different Formulations of BI 1358894 With or Without Food Influences the Amount of BI 1358894 in the Blood
The main objective of this trial is to investigate the relative bioavailability of a single dose of BI 1358894 administered as tablet formulation 2 (TF2a, TF2b) under fasted conditions compared with the tablet formulation 1 (TF1)…
- Trial name
- NCT03892616
- Testing
- BI 1358894 (B), BI 1358894 (C), BI 1358894 (D)
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Glycemic Response, Insulinemic Response
Glycemic and Insulinemic Impact of a Test Granola 3 Versus a Control Granola
The objectives of this study are to examine the blood glucose and serum insulin response elicited by servings of Test Granola and Control Granola containing equal amounts of available carbohydrate over a 3 h time period.
- Conditions
- Glycemic Response, Insulinemic Response, Subjectvie Hunger
- Trial name
- NCT03491514
- Testing
- Test Granola, Control Granola
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- PepsiCo Global R&D
Down Syndrome
A Non-Drug Study of The Suitability of Neurocognitive Tests And Functioning Scales For The Measurement of Cognitive And Functioning Changes in Individuals With Down Syndrome
This non-drug, longitudinal, multi-center, multi-national study will evaluate the suitability of neurocognitive tests and functioning scales for the measurement of cognitive and functioning changes in individuals with Down…
- Trial name
- NCT01580384
- Where
- 12 sites in United States, Argentina and 5 more
- Volunteers
- 90 people
- Sponsor
- Hoffmann-La Roche
Cirrhosis
Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics
The three objectives of this trial are: 1. To demonstrate that a decline in hepatic metabolic function as measured by BreathID will correlate with changes in CTP and MELD scores in patients with cirrhosis. 2.
- Trial name
- NCT00375011
- Where
- 3 sites in United States, Israel
- Volunteers
- 200 people
- Sponsor
- Meridian Bioscience, Inc.
Heart Failure, Chronic Heart Failure
The HEARTFELT Study
This pragmatic randomized crossover trial looks at the effect(s) of using a remote patient monitoring device (Heartfelt device) with health alerts to monitor the development of peripheral edema in patients with heart failure…
- Trial name
- HEARTFELT (NCT06222099)
- Testing
- Heartfelt Device installed, Standard care, Heartfelt-guided care
- Where
- 3 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Heartfelt Technologies
Wave Form Signals Coming From the Eye in a Healthy Cohort
Neuro-ocular Baselines in a Sports Setting
Rebion (Rebiscan, Inc) has developed a noninvasive, handheld device that uses retinal birefringence scanning (RBS) to rapidly assess eye fixation and retinal integrity in adults and children.
- Trial name
- KY (NCT03653936)
- Testing
- HITT device
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Rebiscan, Inc.
Cancer
Does Screening With the Galleri Test in the NHS Reduce the Likelihood of a Late-stage Cancer Diagnosis in an Asymptomatic Population? A Randomised Clinical Trial
The Galleri test is a new test that looks for potential signs of cancer in a blood sample. The test can find many different types of cancer but cannot find all cancers.
- Trial name
- NHS-Galleri (NCT05611632)
- Testing
- Multi-cancer early detection test (Galleri test)
- Where
- United Kingdom
- Volunteers
- 142,318 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Healthy Participants, Epilepsy
A Study to Test the Blood Concentration of 4 Padsevonil Product Variants and the Effect of Food on Padsevonil
The purpose of the study in Part 1, is to evaluate (under fasted conditions) the plasma pharmacokinetics (PK) of padsevonil (PSL) using 4 PSL product variants against a PSL reference tablet and in Part 2, to evaluate the PK of…
- Trial name
- NCT04283136
- Testing
- Padsevonil type 1 Tablet 200 mg, Padsevonil type 2 Tablet, Padsevonil type 3 Tablet
- Volunteers
- healthy volunteers welcome
- Sponsor
- UCB Biopharma SRL
Healthy
Bioequivalence Study of Quetiapine Fumarate Tablets 300 mg Under Fasting Condition
This is an open label, randomised, balanced, two-treatment, two-period, two-sequence, crossover, multicentric experimental bioequivalence study.
- Trial name
- NCT01566487
- Testing
- Quetiapine fumarate
- Where
- India
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Dry Eye, Sjogren's Syndrome
Pilot Study for Testing Safety of Repetitive Magnetic Stimulation for Treatment of Dry Eye
The study aims to test the safety of Repetitive Magnetic Stimulation (RMS) treatment for dry eye disease. Patients are asked to undergo a one-time treatment with Epitech Ocular Magnetic Stimulation Device on one eye in the first…
- Conditions
- Dry Eye, Sjogren's Syndrome, Aqueous Tear Deficiency, Meibomian Gland Dysfunction
- Trial name
- NCT03012698
- Testing
- Ocular Repetitive Magnetic Stimulation (RMS) treatment
- Where
- 3 sites in Israel
- Volunteers
- 29 people
- Sponsor
- Epitech Mag Ltd.
Fibromyalgia
A Study to Test the Effectiveness and Safety of Fremanezumab on Participants With Fibromyalgia
The primary objective of the study is to estimate the treatment effect of fremanezumab administered subcutaneously (SC) in reducing pain in adult participants with fibromyalgia (FM).
- Trial name
- NCT03965091
- Testing
- Fremanezumab
- Where
- 49 sites in United States
- Volunteers
- 189 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.